Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ: QNCX )

1.901 +0.310 (+19.53%)
Streaming Delayed Price Updated: 3:47 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
This Six Flags Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Quince Therapeutics to Participate at Upcoming Investor Conferences
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
From Quince Therapeutics, Inc.
Via Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024
Quince Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
From Quince Therapeutics, Inc.
Via Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
Quince Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023
Quince Therapeutics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Launches Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Participate at Investor Events in January 2024
From Quince Therapeutics, Inc.
Via Business Wire
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
From Quince Therapeutics, Inc.
Via Business Wire
Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket
Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.